Crizotinib-induced immunogenic cell death in non-small cell lung cancer
Open Access
- 2 April 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Communications
- Vol. 10 (1), 1486
- https://doi.org/10.1038/s41467-019-09415-3
Abstract
Immunogenic cell death (ICD) converts dying cancer cells into a therapeutic vaccine and stimulates antitumor immune responses. Here we unravel the results of an unbiased screen identifying high-dose (10 µM) crizotinib as an ICD-inducing tyrosine kinase inhibitor that has exceptional antineoplastic activity when combined with non-ICD inducing chemotherapeutics like cisplatin. The combination of cisplatin and high-dose crizotinib induces ICD in non-small cell lung carcinoma (NSCLC) cells and effectively controls the growth of distinct (transplantable, carcinogen- or oncogene induced) orthotopic NSCLC models. These anticancer effects are linked to increased T lymphocyte infiltration and are abolished by T cell depletion or interferon-γ neutralization. Crizotinib plus cisplatin leads to an increase in the expression of PD-1 and PD-L1 in tumors, coupled to a strong sensitization of NSCLC to immunotherapy with PD-1 antibodies. Hence, a sequential combination treatment consisting in conventional chemotherapy together with crizotinib, followed by immune checkpoint blockade may be active against NSCLC.This publication has 51 references indexed in Scilit:
- ALK in Lung Cancer: Past, Present, and FutureJournal of Clinical Oncology, 2013
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with VemurafenibThe New England Journal of Medicine, 2012
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung CancersScience Translational Medicine, 2012
- The secret ally: immunostimulation by anticancer drugsNature Reviews Drug Discovery, 2012
- Induction of Immunogenic Apoptosis by Blockade of Epidermal Growth Factor Receptor Activation with a Specific AntibodyThe Journal of Immunology, 2011
- Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumorsNature Medicine, 2011
- Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinaseNature Protocols, 2009
- Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell deathThe EMBO Journal, 2009
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsThe New England Journal of Medicine, 2002